ACRV
Acrivon Therapeutics, Inc.
$2.04
+0.18 (+9.68%)
At close · Jul 8
Market Cap
$87.74M
Shares
42,801,729
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.04
Open$1.86
Day$1.82–2.05
52W$1.20–3.56
Avg vol 30d373K
Short int2.8M · 6.6% float · 8.2d
Short vol51%
Last earningsMay 26, 2026
DataNov 2022–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
+18%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
36%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+45%
trailing
6-month return
+20%
trailing
YTD return
−15%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.61% of float · ▲ +0.9% MoM · 8.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
44 holders — mid 3-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
EPS growth
+15%
Y/Y
Free cash flow
$-65.3M
Balance sheet
$41.5M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Nov 23, 2026
Est · unconfirmed
· in 19 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
+18%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
36%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-8% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.61% of float · ▲ +0.9% MoM · 8.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
44 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 36%
52-wk high $4
vs 200-day avg +9%
vs 50-day avg +18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACRV
this stock
Acrivon Therapeutics, Inc.
|
$87.74M | -15.4% | — | — | 6.6% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACRV | +14.6% | +44.7% | +20.0% | +14.6% | -15.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +14.8% | +43.8% | +12.6% | +14.8% | -24.7% |